• Tempest Therapeutics received a Nasdaq notice on May 19, 2026, citing non-compliance with the $2.5 million minimum stockholders’ equity requirement after reporting $822,000 as of March 31, 2026.
• Nasdaq gave the company 45 days, through July 6, 2026, to submit a plan to regain compliance; an accepted plan could allow up to a 180-day extension to cure the deficiency.
• Separate Nasdaq notices dated May 22, 2026, flagged board and committee independence shortfalls following director resignations, triggering another requirement to submit a compliance plan within 45 days.
• The notices do not immediately affect trading on the Nasdaq Capital Market, but failure to win approval for the plans or regain compliance could lead to a delisting process, including an appeal to a Nasdaq hearings panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-237207), on May 22, 2026, and is solely responsible for the information contained therein.